Clinical trials
Hypersensitivity trials in Norway
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Active, not recruiting | 4 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital of North Norway | 5 |
| Haukeland University Hospital | 3 |
| Cogent Biosciences, Inc. | 2 |
| Oslo University Hospital | 2 |
| St. Olavs Hospital | 2 |
| AstraZeneca | 1 |
| GlaxoSmithKline | 1 |
| Norwegian Institute of Public Health | 1 |
| Norwegian University of Science and Technology | 1 |
| Novartis Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypersensitivity | 20 |
| Asthma | 4 |
| Hypersensitivity, Immediate | 3 |
| Immune System Diseases | 3 |
| Breast Neoplasms | 2 |
| Dermatitis, Atopic | 2 |
| Hematologic Diseases | 2 |
| Immune Complex Diseases | 2 |
| Mastocytosis | 2 |
| Mastocytosis, Systemic | 2 |
Trials
Showing 51 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.